Overview
Hims & Hers Q3 revenue grows 49% yr/yr, beating analyst expectations
Adjusted EBITDA for Q3 increases 53% yr/yr, reflecting strong operational execution
Company in talks with Novo Nordisk to offer Wegovy injections, no agreement yet
Outlook
Company expects Q4 2025 revenue of $605 mln to $625 mln
Hims & Hers narrows full-year 2025 revenue guidance to $2.335 bln to $2.355 bln
Company anticipates full-year 2025 adjusted EBITDA of $307 mln to $317 mln
Result Drivers
SUBSCRIBER GROWTH - Subscriber base increased by 21% yr/yr, contributing to revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $600 mln | $580.24 mln (12 Analysts) |
Q3 EPS | $0.06 | ||
Q3 Net Income | $16 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 10 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Hims & Hers Health Inc is $48.00, about 5.3% above its October 31 closing price of $45.46
The stock recently traded at 60 times the next 12-month earnings vs. a P/E of 80 three months ago
Press Release: ID:nBw8x1gkta
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
